Wolters Kluwer and Radiological Society of North America Establish 10-Year Agreement to Advance Global Access to Leading Radiology Research Journals Wolters Kluwer Health announced a new 10-year agreement to publish the Radiological Society of North America (RSNA) portfolio of five specialty journals…
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model Turn Therapeutics Inc. a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, announced the publication of…
Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer Medifast, Inc. announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue…
Octave Bioscience Accelerates Precision Neurology Momentum, Appoints Zachary Fernandes as VP of Business Development to Scale Strategic Partnerships Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker-driven solutions for multiple sclerosis, Parkinson’s and other neurodegenerative diseases, today announced…
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, announced that it will present new preclinical data on TFG-001 at the 7th…
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis Baszucki Group announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic…
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under…
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026 Flatiron Health announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 – June 2, 2026, in Chicago, Illinois. Flatiron’s high-quality…
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Savara Inc. a clinical stage biopharmaceutical company focused on rare respiratory diseases,…
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer Bayer announced that the U.S. Food and Drug Administration (FDA) has granted HYRNUO® (sevabertinib) Priority Review status for…
Massive Bio and Just Worldwide Announce Strategic Partnership to Connect More Cancer Patients to Clinical Trials Massive Bio, the global leader in AI-driven clinical trial matching for cancer patients, and Just Worldwide, a leading global fieldwork and market research provider…
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes Mirum Pharmaceuticals, Inc. a leading rare disease company, announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible senior…